skip to main content skip to footer

Pycongenol

New Star In The Join Pain Area

Exciting research from the April, 2008 Journal: Phytotherapy Research (see below) indicates some spectacular results for people taking 100 mgs of pycnogenol per day for knee pain.  156 people were separated into a pycnogenol group (77) and placebo group (79).  Those taking pycnogenol had a 56% reduction in their WOMAC score (and extensive knee pain questionnaire) indicating significant reductions in knee pain.  In addition their treadmill walking distance increased from 68 meters at baseline to 198 meters after 3 months of treatment. Seventy-six percent of the patients in the treatment group had swelling of their feet at the beginning of the study.  After 3 months the swelling had decreased in 79% of them.  Additionally, the use of drugs decreased by 58% and Gastrointestinal complications decreased by 63% in the pycnogenol group.  Conversely, no significant improvements were found in any of these categories in the placebo group.  The researchers concluded "Pycnogenol offers an option for reduction of treatment costs and side effects by sparing anti-inflammatory drugs."

New findings, of a joint German and Italian study, published in the December, 2008 journal: Redox Reports (see below), indicate that supplements with Pycnogenol may be able to reduce levels of C-Reactive Protein (CRP),  a marker of inflammation.  The pycnogenol supplementation worked sufficiently well to prevent a ‘spill-over’ of this inflammatory marker from the joints into the whole body.

Dr. Peter Rohdewald, a lead researcher of the study, said "The decrease of systemic inflammatory markers, particularly CRP, suggests Pycnogenol properties may be potent enough to arrest the spread of inflammation from osteoarthritic joints to the whole organisms""When inflammatory processes are allowed to reach the whole body the degenerative processes may burden overall health including increased cardiovascular risks." CRP has been reported as an independent predictor of cardiovascular-related events.

---- BACKNOBBER II IN USE MODEL3A (thumb) At this point Pycnogenol, at 100mgs per day (preferably- 50mgs BID), is a good nutrient to try for anyone suffering with knee pain or general joint pain.  I personally  have found good benefit.

 Additionally, many of my patients find that they enjoy wonderful back and neck pain relief with the---- BIOFREEZE WITH ILEX PAIN RELEIVING GEL - 4 FL OZ TUBE (large) Backnobber II (pictured at left).  The Backnobber allows  you to perfom trigger point therapy on those painful, hard to reach places.  Great for  neck pain, upper back pain, mid back pain and shoulder pain.

 BioFreeze, pain relieving linament, can also be quite helpful for joint and muscle pain.  Rub vigorously for a minute or two directly on the effected joint or    muscle.  Many of my patients swear by it.  Click the link for great pricing on various sizes of BioFreeze. 

 Good luck and feel free to call with any questions.
 


In Health,
Dr. Neil Levin
Chiropractor practicing in East Northport, NY
(631) 651-2929

See Reasearch Below 

Redox Rep. 2008;13(6):271-6.

Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol.
Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, Ledda A, Di Renzo A, Stuard S, Dugall M, Pellegrini L, Gizzi G, Ippolito E, Ricci A, Cacchio M,Cipollone G, Ruffini I, Fano F, Hosoi M, Rohdewald P.

In a previous, double-blind, placebo-controlled study we evaluated the efficacy of a 3-month treatment with Pycnogenol for 156 patients with osteoarthritis of the knee. Pycnogenol significantly decreased joint pain and improved joint function as evaluated using the WOMAC score and walking performance of patients on a treadmill. In this study, we further investigated the anti-inflammatory and antioxidant activity of Pycnogenol in a subset of the osteoarthritis patients presenting with elevated C-reactive protein (CRP) and plasma-free radicals. Elevated CRP levels have been suggested to be associated with disease progression in osteoarthritis. In our study, 29 subjects of the Pycnogenol group and 26 patients in the placebo group showed CRP levels higher than 3 mg/l at baseline. Comparison of blood specimens drawn at baseline and after 3-month treatment showed that Pycnogenol significantly decreased plasma free radicals to 70.1% of baseline values. Plasma CRP levels decreased from baseline 3.9 mg/l to 1.1 mg/l in the Pycnogenol group whereas the control group had initial values of 3.9 mg/l which decreased to 3.6 mg/l. The CRP decrease in the Pycnogenol was statistical significant as compared to the control group (P < 0.05). Fibrinogen levels were found to be lowered to 62.8% of initial values (P < 0.05) in response to Pycnogenol. No significant changes for plasma free radicals, CRP and fibrinogen were found in the placebo-treated group. The decrease of systemic inflammatory markers suggests that Pycnogenol may exert anti-inflammatory activity in osteoarthritic joints and patients did not present with other ailments or infections. The nature of the anti-inflammatory effects of Pycnogenol with regard to CRP warrants further investigation.

PMID: 19017467 [PubMed - in process]

  Phytother Res. 2008 Apr;22(4):518-23. 

Treatment of osteoarthritis with Pycnogenol. The SVOS (San Valentino Osteo-arthrosis Study). Evaluation of signs, symptoms, physical performance and vascular aspects.

Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, Ledda A, Di Renzo A, Stuard S, Dugall M, Pellegrini L, Errichi S, Gizzi G, Ippolito E, Ricci A, Cacchio M, Cipollone G, Ruffini I, Fano F, Hosoi M, Rohdewald P.

Irvine2 Vascular Laboratory, Department of Biomedical Sciences, Chieti-pescara University and San Valentino Vascular Screening Project, San Valentino, PE, Italy. cardres@aol.it

The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of 100 mg Pycnogenol daily (oral capsules) in a 3 month study in patients with osteoarthritis (OA). OA symptoms were evaluated by WOMAC scores, mobility by recording their walking performance (treadmill). Treatment (77 patients) and placebo group (79) were comparable for age, sex distribution, WOMAC scores, walking distances and use of antiinflammatory drugs. The global WOMAC score decreased by 56% (p < 0.05) in the treatment group versus 9.6% in the placebo group. Walking distance in the treadmill test was prolonged from 68 m at the start to 198 m after 3 months treatment (p < 0.05), under placebo, from 65 m to 88 m (NS). The use of drugs decreased by 58% in the treatment group (p < 0.05) versus 1% under placebo. Gastrointestinal complications decreased by 63% in the treatment group, but only 3% under placebo. Overall, treatment costs were reduced significantly compared with placebo. Foot edema was present in 76% of the patients of the treatment group at inclusion and in 79% of the controls. After 3 months edema decreased in 79% of Pycnogenol patients (p < 0.05) vs 1% in controls. In conclusion, Pycnogenol offers an option for reduction of treatment costs and side effects by sparing antiinflammatory drugs. (c) 2008 John Wiley & Sons, Ltd.

PMID: 18386255 [PubMed - indexed for MEDLINE]